Organization
Tempus AI
1 clinical trial
14 abstracts
Clinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 MutationsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Abstract
Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC).Org: Cedars-Sinai Medical Center, City of Hope National Medical Center, Washington University in St. Louis, Allegheny Health Network Cancer Institute, Tempus AI,
Abstract
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.Org: Tempus AI, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Ochsner Health Center, Johns Hopkins University,
Abstract
TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment.Org: TriHealth Cancer Institute, Tempus AI,
Abstract
Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy.Org: Tempus AI, Tempus Labs, Inc., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Washington University School of Medicine in St. Louis,
Abstract
Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB).Org: University of California, San Diego Health, Tempus AI, University of California, Irvine Medical Center, Cleveland Clinic Taussig Cancer Institute, University of Washington, Fred Hutchinson Cancer Center,
Abstract
Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung.Org: Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Tempus AI, Tempus Labs, Inc.,
Abstract
Use of a deep learning model on H&E slides to predict nucleic acid yield for NGS testing.Org: Tempus AI, Chicago, IL, Il-Yang Pharmaceuticals,
Abstract
Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population.Org: Tempus AI, Chicago, IL, AstraZeneca, Waltham, MA, AstraZeneca R&D Boston,
Abstract
Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional, real-world data.Org: Ochsner Health Center, Tempus AI,
Abstract
Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM).Org: EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA, Tempus AI,
Abstract
Racial and genetic ancestry associations with gene expression patterns in a real-world cohort of colorectal cancer patients.Org: UT Southwestern Medical Center, Tempus AI, Tempus Labs, Inc.,
Abstract
The Tempus TIME trial portal and clinical trial enrollment.Org: Memorial Care, Fountain Valley, CA, CanSino Biologics, OhioHealth, Columbus, OH,
Abstract
Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.Org: Tempus Labs, Inc., Tempus AI, University of Southern California Marshall School of Business,
Abstract
Genomic characterization of vulvar squamous cell carcinoma to reveal differential gene expression based on clinical outcome.Org: Norton Cancer Institute, Tempus AI, CPA Laboratory, Norton Healthcare,